Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-07 · 399 (10) · 14659-14676
DOI: 10.1007/s00210-026-05309-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 23.04.2026. Verfasst von Ayman Ali Mohammed Alameen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, P.O. Box 2014, Sakaka, KSA, Saudi Arabia. aaalameen…. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Senotherapeutics, Brain, Aging. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 165 Literaturangaben.
Abstract (Originalsprache)
Cellular senescence, driven by the interaction between FOXO4 and p53, is increasingly recognized as a crucial mechanism in brain aging and the development of neurodegenerative disorders. The senolytic peptide FOXO4-DRI, which has been thoughtfully designed, selectively disrupts the FOXO4-p53 complex, inducing apoptosis in senescent cells while preserving healthy tissue. In aged mammalian models, administering FOXO4-DRI decreases the accumulation of senescent cells, restores cerebral blood flow and the integrity of the blood-brain barrier (BBB), reverses hippocampal atrophy, and enhances cognitive function. Furthermore, in models of Alzheimer's disease (AD) and tauopathy, this intervention eliminates amyloid-β and pathological tau, leading to improved memory performance. Preliminary human studies involving FOXO4-axis modulators, such as high-dose fisetin, show a reduction in the senescence-associated secretory phenotype (SASP) and enhancements in cognitive and physical measures among older adults. These findings collectively identify the FOXO4-p53 axis as a potential pharmacological target in brain aging and highlight senolytic therapy as a promising strategy for altering diseases to postpone or reverse age-related cognitive decline. This review consolidates recent findings indicating that FOXO4-dependent senescence significantly contributes to neuroinflammation, synaptic dysfunction, and impaired neurogenesis in the aging brain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, P.O. Box 2014, Sakaka, KSA, Saudi Arabia. aaalameen@ju.edu.sa.
- Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Arish Branch, Sinai University, Arish, 45511, Egypt. mohamed.naser@su.edu.eg.
- Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, 22511, AlBeheira, Egypt. Gaberelsaberbatiha@gmail.com.
Zitieren
APA
Alameen, A. A. M., Al-Kuraishy, H. M., Fawzy, M. N., & Batiha, G. E. (2026). Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(10), 14659-14676. https://doi.org/10.1007/s00210-026-05309-6
Vancouver
Alameen AAM, Al-Kuraishy HM, Fawzy MN, Batiha GE. Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(10):14659-14676. doi:10.1007/s00210-026-05309-6
BibTeX
@article{Alameen2026,
author = {Alameen, Ayman Ali Mohammed and Al-Kuraishy, Hayder M and Fawzy, Mohamed N and Batiha, Gaber El-Saber},
title = {Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {10},
pages = {14659--14676},
doi = {10.1007/s00210-026-05309-6}
}
EUVIMED